Exploring the role of pancreatic enzyme replacement therapy in patients with short bowel syndrome: Nutritional and Anthropometric Outcomes.

BACKGROUND

Pancreatic enzyme replacement therapy (PERT) has been proposed as a treatment for patients with short bowel syndrome (SBS) to address fat malabsorption and promote growth. However, research on the effectiveness of PERT in this population remains limited. This study aims to investigate the impact of PERT on nutritional status and anthropometric measurements in individuals with SBS.

MATERIAL AND

METHODS

We retrospectively analyzed medical records of 14 patients with SBS under 25 years at our institution who were prescribed PERT over a twelve-year period. Nutritional status factors including enteral and parenteral calorie intake, fat-soluble vitamin deficiency, vitamin supplement use, along with anthropometric measurements, were assessed across three-time frames: 6 months pre-PERT administration, at PERT initiation, and 6 months post-PERT. Statistical tests, including Mann-Whitney rank sum, Chi-squared, and regression tests, were conducted with a significance level set at 0.05.

RESULTS

Of the 14 patients with SBS who were using PERT, six had elastase levels suggesting pancreatic insufficiency (PI). Among the 14 patients, one discontinued parenteral nutrition (PN) support after 6 months of PERT. Fat soluble vitamin deficiency persisted among three patients despite vitamin supplementation. Six months post-PERT, there was a non-significant decrease in all mean anthropometric z-scores, except for the weight z-scores (p > 0.84). Significant decreases in mean BMI z-scores (p = 0.03) and non-significant reductions in all remaining anthropometric measurements (p > 0.13) were observed among patients with PI following 6 months of PERT use.

CONCLUSION

PERT utilization may not significantly address fat malabsorption or promote growth in patients with SBS, likely due to anatomical constraints of a shortened bowel that affect nutrient absorption. Further investigation is warranted to determine the efficacy of PERT as a treatment tool for patients with SBS.